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Background: Although low-dose aprotinin administered after cardiopulmonary
bypass has been reported to reduce mediastinal blood loss and blood product
requirements in patients not taking aspirin, it is unknown whether low-dose post-
operative aprotinin has any beneficial effects in patients undergoing coronary artery
bypass operations who are at high risk of excessive postoperative bleeding and
increased transfusion requirements because of aspirin use until just before the oper-
ation.
Methods:  Fifty-five patients undergoing primary coronary artery operations with
cardiopulmonary bypass who continued taking aspirin (150 mg/d) until the day
before the operation were enrolled in a prospective, randomized, double-blind trial
to receive a single dose of either placebo (n = 29) or 2 × 106 kallikrein inhibiting
units of aprotinin (n = 26) at the time of sternal skin closure.
Results:  Patients in the aprotinin group had a lower rate (28 ± 18 vs 43 ± 21 mL/h
[mean ± standard deviation], P < .005) and total volume of mediastinal drainage
(955 ± 615 vs 1570 ± 955 mL, P < .007), as well as a shorter duration of mediasti-
nal drain tube insertion (24.4 ± 13.8 vs 31.3 ± 16.5 hours, P < .05). In addition, a
smaller proportion of patients receiving aprotinin required a blood product (31% vs
62%, P = .03), resulting in a reduction in the use of packed cells by 47% (P = .05),
platelets by 77% (P = .01), fresh frozen plasma by 88% (P = .03), and total blood
products by 68% (P = .01) in this group.
Conclusions: These results suggest that postoperative administration of low-dose
aprotinin in patients taking aspirin until just before primary coronary artery operations
with cardiopulmonary bypass not only reduces the rate and total amount of postoper-
ative mediastinal blood loss but also lowers postoperative blood product use.
Cardiopulmonary bypass (CPB) is associated with the induction of atransient hemostatic defect that appears to be related to a variety offactors, including platelet dysfunction caused by reduced surfaceexpression of glycoproteins Ib and IIb-IIIa, activation of coagulationpathways with consumption of clotting factors, and increases in fi-brinolytic activity.1 By increasing the risk of excessive postoperative
bleeding, this hemostatic defect predisposes to increased blood product use and reop-
eration for bleeding and thus makes a major contribution to postoperative morbidity
and mortality after cardiac operations.2 Meta-analysis of a large number of random-
ized controlled trials has established that prophylactic administration of the serine
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protease inhibitor aprotinin before and during CPB not only
reduces postoperative blood loss3,4 but also lowers transfu-
sion requirements,3-5 the frequency of surgical re-exploration
for bleeding,4,5 and overall operative mortality.4
Aprotinin is, however, quite expensive, with a calculated
cost of approximately $1000 in US currency per procedure
for the commonly used high-dose perioperative regimen.3
Moreover, concerns have also been raised about this regi-
men with respect to an increased risk of acute myocardial
infarction, renal dysfunction, and graft occlusion.1,6,7 For
these reasons, several prospective, placebo-controlled stud-
ies have examined the effect of administering low-dose
aprotinin on discontinuation of CPB.8-10 Such studies have
shown that in patients who were not taking aspirin or who
discontinued aspirin for at least 7 days before the operation,
low-dose postoperative aprotinin reduces postoperative
mediastinal blood loss with9,10 or without8 a significant
reduction in the use of blood products. It is unknown, how-
ever, whether low-dose aprotinin administered after CPB
has any beneficial effects in patients taking aspirin until just
before the cardiac operation, a subgroup that is known to be
at high risk of excessive postoperative bleeding and
increased transfusion requirements.11-13
Accordingly, the purpose of this single-center, prospec-
tive, double-blind, placebo-controlled study was to deter-
mine whether a single low-dose bolus of aprotinin given at
the end of CPB reduced mediastinal drainage or blood prod-
uct use in patients undergoing primary coronary artery
bypass grafting (CABG) who had been receiving aspirin
therapy until just before the operation.
Patients and Methods
Patient Selection
The study was performed in accordance with the guidelines of the
National Health and Medical Research Council of Australia and
approved by the Human Research and Ethics Committee at
Monash Medical Center. Of the 64 consecutive patients referred to
one surgeon (J.M.A.) for primary elective or urgent CABG with
CPB between February and July 1998 who were considered suit-
able for enrollment in the study, 4 declined to participate; a further
5 were deemed ineligible for inclusion because of a preoperative
bleeding diathesis (n = 1), extensive pericardial adhesions detect-
ed at the time of the operation (n = 1), or incomplete postoperative
data sets (n = 3). The study cohort therefore comprised 55 patients
who gave informed consent to participate in the study and who
continued aspirin (150 mg/d) as part of medical management of
their coronary vascular disease until the day before the operation
but did not receive any other preoperative antiplatelet medication.
The sample size of the aprotinin and placebo groups (n > 23) was
calculated on the basis of an expected difference in mediastinal
blood loss between groups of 400 mL (standard deviation [SD],
400 mL), a 2-tailed α value of less than .05, and a β value of .9.
Patients were randomized by a computer-generated random
number sequence into an aprotinin (n = 26) and a placebo (n = 29)
group. All clinical participants were double-blinded until the com-
pletion of the trial. A designated pharmacy liaison officer was
responsible for the randomization, as well as for the preparation of
placebo and treatment solutions, which were identical in their
appearance and packaging. Patients initially received a test dose of
aprotinin or placebo in the operating theater after the completion
of sternal skin closure. If no adverse reaction occurred to the test,
then either a total of 2 × 106 kallikrein inhibiting units (KIU) of
aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) or an equal
volume of placebo (normal saline solution) was infused over
approximately 20 minutes.
Operative Procedure
Anesthetic and CPB management were standardized for all study
patients. CPB was performed with a hollow-fiber membrane oxy-
genator (Cobe Duo, Arvada, Colo) and a vortex centrifugal pump
(Medtronic BioMedicus, Eden Prairie, Minn). Hypothermia to
32°C was used in all cases. Cardioplegic arrest was induced by
using antegrade and retrograde blood cardioplegia (Viaflex;
Baxter, Toongabbie, New South Wales, Australia). On completion
of each distal anastomosis, a further bolus of cold blood cardio-
plegic solution was given. After completion of the last distal anas-
tomosis, warm substrate-enriched cardioplegic solution was deliv-
ered, and the aorta-coronary anastomoses were completed by
means of a side-biting aortic clamp. With the exception of 1 patient
in whom a saphenous vein graft was used, the left internal thoracic
artery was used to graft the left anterior descending coronary
artery, and radial artery and saphenous vein grafts were used as
required. After discontinuation of CPB, all blood in the CPB cir-
cuit was returned to the patient in the operating theater.
Anticoagulation was achieved with sodium heparin (300 IU/kg)
and monitored with serial measurements of the activated clotting
time (ACT) performed with a kaolin-activated Hemotec device
(Medtronic Hemotec Inc, Englewood, Colo). The ACT was main-
tained above 450 seconds at all times during CPB. At completion
of CPB, heparin was reversed with protamine sulfate given in a 1:1
ratio. After this dose, a further 100 mg of protamine was given if
the ACT remained above 140 seconds, whereas an additional 50
mg of protamine was administered if the ACT was between 120
and 140 seconds.
Postoperative Measurements
Hemoglobin concentration, platelet count, fibrinogen level, and
serum creatinine level were measured before the operation, on
arrival of patients into the intensive care unit (ICU), and on days 1
and 5 after the operation, whereas the activated partial thrombo-
plastin time (APTT) and international normalized ratio were mea-
sured before and immediately after the operation. Mediastinal
drainage was measured at hourly intervals in the ICU, and medi-
astinal drains were removed when blood loss was less than 100 mL
over 4 hours.
All patients had an electrocardiogram immediately after the opera-
tion and on postoperative days 1, 2, and 5, whereas serial creatine
kinase (CK) MB isoenzyme measurements were performed on days 1
and 2. The diagnosis of myocardial infarction was made if the CK-MB
level was greater than 5% of the total CK level and/or if new Q waves,
a new left bundle branch block, or ST-segment elevation of greater than
2 mm in 2 consecutive leads were present on the electrocardiogram.
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Blood Product Transfusion Policy
Clear criteria for transfusion of blood products were established
before the start of the trial. No patient received any blood product
unless prior approval was given by either the cardiac surgeon or a
delegated surgical trainee, barring an emergency. Blood products
were administered after clinical consideration of the rate and total
amount of blood loss, and the type of blood product used was
based on the results of hematologic tests. Thus, homologous
packed red cells were given if the hemoglobin concentration was
less than 80 g/L, platelets were given if the platelet count was less
than 90 × 109/L, fresh frozen plasma was given if the internation-
al normalized ratio was greater than 1.5, and cryoprecipitate was
given if the serum fibrinogen level was less than 1 g/L. No drug
other than aprotinin was administered to reduce postoperative
bleeding. Return to the operating theater was considered if medi-
astinal blood loss exceeded 500 mL in 1 hour or 400 mL over 2
hours or was greater than 100 mL/h for 3 consecutive hours.
Statistical Analyses
Statistical analyses were performed with the Statistical Package for
the Social Sciences, Version 9.0.1 (SPSS Inc, Chicago, Ill).
Statistical comparisons were performed with the Student t test for
normally distributed variables, a Mann-Whitney test for nonnor-
mally distributed data, and the χ2 test for discrete variables. On the
basis of the visual impression that a linear relationship existed
between cumulative blood loss and time in the initial postoperative
period,8,10 postoperative mediastinal drainage patterns were evalu-
ated with mediastinal drainage-time relationships, which were
constructed by plotting the cumulative drainage at 2-hour intervals
for the initial 14 to 20 hours after the operation and analyzed with
linear regression. The average regression line for each group was
determined with the average slope method of Colquhoun,14 in
which the average slope and intercept were obtained from the
weighted individual values. Results are expressed as means ± SD.
Results
The placebo and aprotinin groups were well matched with
respect to their demographic features, CPB times, and
heparin and protamine doses, as well as the number and
type of vascular conduits used for grafting (Table 1). Apart
from a higher serum creatinine level and APTT in the apro-
tinin group after arrival in the ICU, no significant differ-
ences in hematologic and biochemical variables were evi-
dent between the 2 groups before or after the operation
(Table 2). Moreover, no deaths, perioperative myocardial
infarctions, strokes, or acute renal failure occurred in either
group, and no patient was returned to the operating theater
for any reason.
Mediastinal Drainage
In the placebo group the cumulative mediastinal drainage
was 630 ± 300 mL at 4 hours, 975 ± 430 mL at 12 hours,
1340 ± 560 mL at 24 hours, and 1570 ± 955 mL at removal
of the drain tubes. Mediastinal drainage in the aprotinin
group was 33% to 40% lower over the corresponding time
points, with volumes of 420 ± 180 mL at 4 hours (P = .002),
650 ± 275 mL at 12 hours (P < .02), 890 ± 430 mL at 24
hours (P = .002), and 955 ± 615 mL at the time of chest tube
removal (P = .007, Figure 1). Furthermore, removal of chest
drains after the operation occurred sooner in the aprotinin
group (24.4 ± 13.8 hours) than in the placebo group (31.3 ±
16.5 hours, P < .05).
TABLE 1. Patient characteristics
Placebo (n = 29) Aprotinin (n = 26) P value
Age (y) 64 ± 8 63 ± 8 .62
Sex (M:F) 22:7 23:3 .3
Weight (kg) 75.9 ± 12.6 81.0 ± 12.4 .14
Height (cm) 168 ± 7 168 ± 14 .99
Urgent cases 10 (34%) 9 (35%) .99
Bypass time (min) 76 ± 22 70 ± 21 .31
Heparin dose (IU/kg) 363 ± 90 374 ± 118 .7
Protamine dose (mg) 400 ± 104 408 ± 78 .76
No. of grafts 3.3 ± 1.0 3.3 ± 0.9 .9
Internal thoracic artery 1.1 ± 0.3 1.1 ± 0.4 .78
Radial artery 0.9 ± 0.6 0.6 ± 0.5 .06
Saphenous vein 1.3 ± 1.2 1.7 ± 1.2 .28
Results are expressed as means ± SD.
TABLE 2. Preoperative and postoperative hematologic and
biochemical data
Placebo (n = 29) Aprotinin (n = 26) P value
Preoperative
Hemoglobin (g/L) 139 ± 12 141 ± 11 .45
Platelets (109/L) 209 ± 40 225 ± 45 .17
Fibrinogen (g/L) 2.6 ± 0.5 2.5 ± 0.3 .55
Serum creatinine (µmol/L) 98 ± 25 101 ± 19 .57
INR 1.0 ± 0.1 1.0 ± 0.0 .28
APTT (s) 36 ± 14 35 ± 14 .79
Immediate postoperative
Hemoglobin (g/L) 91 ± 17 97 ± 17 .22
Platelets (109/L) 122 ± 37 130 ± 29 .37
Fibrinogen (g/L) 2.0 ± 0.3 1.9 ± 0.3 .87
Serum creatinine (µmol/L) 67 ± 19 77 ± 17 <.05
INR 1.3 ± 0.1 1.3 ± 0.1 .95
APTT (s) 38 ± 11 66 ± 15 <.001
First postoperative day
Hemoglobin (g/L) 95 ± 11 101 ± 15 .14
Platelets (109/L) 145 ± 36 155 ± 36 .31
Serum creatinine (µmol/L) 86 ± 21 93 ± 22 .24
INR 1.1 ± 0.1 1.1 ± 0.1 .79
APTT (s) 30 ± 4 33 ± 6 .08
Fifth postoperative day
Hemoglobin (g/L) 104 ± 10 104 ± 17 .86
Platelets (109/L) 246 ± 68 244 ± 54 .94
Serum creatinine (µmol/L) 95 ± 29 95 ± 14 .95
Results are expressed as means ± SD. INR, International normalized ratio;
APPT, activated partial thromboplastin time.
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Mediastinal Drainage-Time Relationships
Representative postoperative mediastinal drainage-time
relationships for patients in the placebo and aprotinin
groups are shown in Figure 2, A, and the average relation-
ships for the 2 groups are depicted in Figure 2, B. The medi-
astinal drainage-time relationships were highly linear in
both the aprotinin (R2 = 0.96 ± 0.06) and placebo (R2 = 0.95
± 0.04) groups. Importantly, however, the average intercept
of the mediastinal drainage-time relationship in the apro-
tinin group (278 ± 143 mL) was 38% less than in the place-
bo group (448 ± 256 mL, P < .005; Figure 2, C).
Furthermore, the average slope of the relationship (ie, the
rate of drainage) in the aprotinin group (28 ± 18 mL/h) was
65% of that of the placebo group (43 ± 21 mL/h, P < .005;
Figure 2, D).
Blood Product Use
After the operation, some form of blood product was used
in 18 (62%) patients of the placebo group but in only 8
(31%) patients of the aprotinin group (P = .03).
Furthermore, aprotinin reduced the use of packed cells from
1.9 ± 2.0 units to 1.0 ± 1.8 units, platelets from 1.7 ± 2.7
units to 0.4 ± 2.0 units, fresh frozen plasma from 1.2 ± 2.2
units to 0.2 ± 0.8 units, and total blood products from 4.8 ±
5.8 units to 1.5 ± 4.2 units (Figure 3). However, in those
patients who required any transfusion, the total amount of
blood product used was not significantly different between
the placebo (7.7 ± 5.7 units) and aprotinin (5.0 ± 6.5 units,
P > .3) groups.
Discussion
The main finding of this single-center, prospective, random-
ized, double-blind, placebo-controlled study was that low-
dose aprotinin given postoperatively had a significant bene-
fit in patients undergoing primary CABG and continuing
with aspirin therapy until just before cardiac operations.
Specifically, the administration of a single dose of 2 × 106
KIU of aprotinin at the time of sternal skin closure in such
patients not only reduced postoperative mediastinal blood
loss by approximately 40% but also halved the number of
patients requiring blood product transfusion in the immedi-
ate postoperative period.
When used prophylactically before CPB, during CPB, or
both, aprotinin is generally given in a high-dose regimen as a
bolus of 2 × 106 KIU before CPB, as a similar dose in the
pump prime, and as a continuous infusion or repeat boluses
during CPB.1,7,15-17 The rationale underlying this regimen is
the attainment of a stable plasma concentration of aprotinin
during CPB that inhibits both the coagulation and fibrinolyt-
Cardiopulmonary Support and Physiology Alvarez et al
Figure 1. Postoperative cumulative mediastinal drainage in placebo
(filled squares) and aprotinin (open squares) patient groups. Results
are presented as means ± SD.
Figure 2. Representative mediastinal drainage-time relationships
in placebo (filled circles) and aprotinin (open circles) groups (A),
as well as average mediastinal drainage-time relationships (B),
intercepts (C), and slopes (D) in placebo and aprotinin groups.
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ic pathways.1 A low-dose prophylactic approach, which con-
sists of the addition of 2 × 106 KIU of aprotinin to the pump
prime, has also been used.17,18 The high-dose aprotinin regi-
men has been shown to be effective in reducing both medi-
astinal blood loss and homologous transfusion requirements
in the absence or presence of pretreatment with aspirin before
cardiac operations,1,16 whereas the low-dose protocol appears
to decrease blood loss but not transfusion requirements in
patients pretreated with aspirin.17,18
The proposition that administration of aprotinin confined to
the period after cessation of CPB might also have a beneficial
effect on postoperative bleeding was initially raised by the
study of Angelini and colleagues,19 which demonstrated that a
bolus of 2 × 106 KIU of aprotinin followed by an infusion of
0.5 × 106 KIU/h had a profound hemostatic effect in 6 patients
exhibiting a life-threatening bleeding diathesis after CPB.
Subsequently, a randomized trial of a similar aprotinin dosage
regimen starting 3 hours after cardiac operations reported a
significant reduction in mediastinal blood loss but not in blood
product use.8 More recent studies have reported that a single 2
× 106 KIU bolus of aprotinin given to patients on arrival in the
ICU after the operation not only reduced mediastinal blood
loss and blood product use9,10 but was as efficacious as high-
dose aprotinin given before and during CPB.9
The effectiveness of low-dose postoperative aprotinin has
only been established in patients who were not taking aspirin
or who had discontinued aspirin for 7 or more days before the
operation.9,10 The question of whether low-dose postopera-
tive aprotinin has any benefit in patients in whom aspirin ther-
apy is continued until the day before the operation has con-
siderable clinical relevance, however, because low-dose
aspirin is normally prescribed as part of routine medical man-
agement in patients with coronary artery disease to reduce
anginal symptoms and the risk of thromboembolic episodes,
myocardial infarction, and death.20,21 Because aspirin use up
until just before the operation increases the risk of excessive
postoperative bleeding,11,12 the likelihood of reoperation for
bleeding,13 and the use of homologous blood and blood prod-
ucts,11,13 aspirin therapy is usually discontinued 5 to 10 days
before an elective coronary vascular operation to reduce the
risk of perioperative blood loss.16,22 It is not always feasible,
however, to delay cardiac operations until the risk of aspirin-
induced bleeding is reduced, particularly in patients undergo-
ing urgent operations, nor is it desirable, such as in patients
with unstable angina and critical high-grade left main steno-
sis (>95%) or triple-vessel disease. Indeed, the proportion of
patients taking aspirin before cardiac operations in published
series is typically in the order of 35%.7
In our study the aprotinin and placebo groups were compa-
rable with respect to baseline characteristics and postoperative
biochemical and hematologic measures, with 2 exceptions.
First, the serum creatinine level was transiently higher by
approximately 15% in the aprotinin group in the initial hours
after drug administration, which is consistent with previous
findings suggesting that aprotinin use may be associated with
reversible renal dysfunction related to its active reabsorption
by the proximal tubules and its gradual metabolism by renal
lysosomal enzymes.1 Second, the APTT of the aprotinin group
was prolonged in the initial ICU sample, which is in accord
with in vitro data23 and the recognized inhibitory action of
aprotinin on contact activation of the intrinsic clotting system.1
The postoperative blood loss in the placebo group of our
study (1570 mL) was within the range of 1515 to 1710 mL
reported in the literature for aspirin-treated patients.16,17
Administration of low-dose aprotinin after CPB had 2 benefi-
cial effects on mediastinal drainage. First, mediastinal
drainage was reduced in the aprotinin group, with the magni-
tude of the reduction in total drainage (approximately 40%)
being within the range of 35% to 49% reported in patients in
whom aspirin was discontinued 7 or more days before the
operation.9,10 In conjunction with this reduced mediastinal
drainage, removal of mediastinal drain tubes occurred, on
average, approximately 7 hours earlier in the group receiving
low-dose postoperative aprotinin.
Use of linear regression analysis to examine the mediastinal
blood loss pattern in greater detail indicated that the decrease in
blood loss after aprotinin in our study was associated with a
reduction in both the intercept and slope of cumulative blood
loss–time relationship. These findings suggest that the reduced
overall mediastinal drainage associated with aprotinin adminis-
tration constituted a combination of 2 effects, namely an initial
fall in drainage occurring in conjunction with drug administra-
tion followed by a persistent reduction in the subsequent rate of
drainage over the first postoperative day. These results are also
in accord with the graphic representation of data presented in
Figure 3. Blood product use in placebo (filled aquares) and apro-
tinin (open squares) patient groups. PC, Packed red cells; FFP,
fresh frozen plasma. Results are presented as means ± SD.
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previous studies in patients not taking aspirin and undergoing
cardiac operations.8,10
The reduction in mediastinal drainage associated with the
use of low-dose postoperative aprotinin in our study had an
additional clinical benefit because it was accompanied by a
reduced use of total blood products, with significant differ-
ences evident in the need for packed cells, platelets, and fresh
frozen plasma. Furthermore, the major factor contributing to
this lesser blood product use was a marked fall in the propor-
tion of patients requiring transfusion after CPB from 62% in
the placebo group to 31% in the aprotinin group, which is sim-
ilar to the corresponding values of 60% to 65% and 32% to
37% reported in patients not receiving aspirin therapy.9,10
Importantly, however, there was no significant difference in
the amount of blood products given to those patients in the
placebo and aprotinin groups requiring transfusion. Taken
together, our observations therefore imply that the fall in blood
product use associated with administration of low-dose post-
operative aprotinin in our study was principally related to a
profound hemostatic effect of this agent in approximately 30%
of patients undergoing CPB, in whom the need for blood prod-
ucts after the operation was avoided.
When given before and after CPB in a high-dose regimen,
aprotinin ameliorates the hemostatic defect produced by CPB
through a prophylactic action mediated by means of inhibition
of plasmin- and kallikrein-mediated fibrinolysis1 and preser-
vation of the platelet membrane glycoprotein 1b adhesion
receptor function.24 However, although the results of our study
and those of others8-10 suggest that postoperative low-dose
aprotinin reduces mediastinal blood loss and blood product
use, the precise mechanisms that underpin the beneficial effect
of this regimen still remain to be defined. Future studies will
be needed to establish the relative extent to which reversals in
the abnormalities of coagulation activity, fibrinolysis, and
platelet function produced by CPB1 contribute to this benefi-
cial effect of postoperative low-dose aprotinin.
Despite its widespread use, one issue that is still not entire-
ly resolved relates to the optimal manner of aprotinin admin-
istration in the setting of a CPB procedure. It has been sug-
gested that many patients treated with aprotinin are
unnecessarily exposed to the potential adverse effects of this
agent and that it may therefore be more prudent to limit use of
this drug to patients exhibiting evidence of excessive bleeding
after CPB.9,10 This proposition was recently examined by
Forestier and colleagues25 in patients who demonstrated active
bleeding during the first 3 hours after arrival in the ICU after
CPB and was shown not to be of any benefit compared with
placebo. However, it is likely that this negative outcome was
influenced by at least 2 factors. First, the timing of postopera-
tive aprotinin dose appears to be important because adminis-
tration up to 3 hours after patient arrival in the ICU produces
only a 25% reduction in mediastinal blood loss without any
fall in blood product use,8 whereas aprotinin administration at
the time of sternal skin closure (present study) or on patient
arrival in the ICU9,10 results in a larger fall in mediastinal
blood loss (35%-49%), as well as a reduction in blood product
use. Second, the dosing schedule of Forestier and colleagues26
(0.2 × 106 KIU bolus followed by an infusion of 0.1 × 106
KIU/h for 8 hours) was estimated to have produced a plasma
aprotinin concentration of 45 to 50 KIU/mL, which is consid-
erably lower than the thresholds of 125 and 250 KIU/mL
reported to be required for inhibition of fibrinolysis and coag-
ulation processes, respectively.1
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